NMDA-based treatment study for major depression
Treatments studied
Part of Mental health clinical trials.
This Phase 2 trial tests whether an NMDA-targeted treatment can improve symptoms of major depressive disorder (MDD). You may be able to join if your depression diagnosis and symptom score fit, and you meet several safety and study-following requirements.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with major depressive disorder (MDD) using DSM-5 criteria
- Your depression symptoms measure high enough on a 17-question Hamilton Depression Scale (score 18 or more)
- You have not taken antidepressant medicines for at least 2 weeks before starting
- You can and agree to participate fully, including signing informed consent and following study rules
- You must not have certain conditions or risks such as bipolar disorder, schizophrenia, or other psychosis
- You should not have recent substance abuse/dependence, serious neurological problems, or moderate-to-severe suicidal risk
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies an NMDA-based treatment for people with major depressive disorder who did not respond to at least one antidepressant. It may help by changing brain signaling linked to depression symptoms.
This trial studies how brain signals measured by MRI and EEG may help doctors choose the best treatment for depression. It focuses on people with early-onset, long-lasting or recurring major depression, and tests whether these “brain biomarkers” track with treatment choice and response.
This study tests an investigational drug called BMS-986511 in adults with moderate to severe depression. The goal is to see if it can improve symptoms.
This trial tests an investigational medication called Azetukalner against a placebo to see if it helps reduce symptoms of major depressive disorder. You may qualify if you are currently in a depressive episode that started in adulthood and have not tried or failed only a few antidepressants.
This trial tests a new medication added to your current treatment for chronic depression that hasn't gotten better with at least two antidepressants and 12 therapy sessions. It might help when standard treatments aren't enough.
This study tests an experimental oral pill called azetukalner against a placebo to see if it safely reduces symptoms of major depressive disorder. It is for adults who are currently in a depressive episode lasting 6 weeks to 2 years and have not already tried multiple antidepressants that failed.
Hear when a new Major Depressive Disorder trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.